Portfolio Lab

Castle Biosciences Inc

  • Stock
  • Ticker CSTL
  • ISIN US14843C1053
  • Nasdaq

Health care · Health care services · USA

$32.86 −1.63%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Castle Biosciences Inc since 07/2019, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CSTLGlobal equities (VT)

$10,000 grew to $5,270. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −88.0% in 06/2023, measured from the peak in 02/2021. The old peak has not been reached again yet.

1-year return
−8.0%
5-year return p.a.
−7.1%
Return p.a. since 07/2019
+6.0%
Volatility p.a.
66.1%
Largest decline
−88.0%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue868886838784104103
Gross profit7072696469638079
Operating income4.1-28-4.3-6.8-3.8-18-3.1-2.7
EBITDA9.81.8-2.8-5.3-0.1-14-1.3-0.7
Net income9.6-264.5-0.5-2.3-15-2.1-4.1
Earnings per share0.32-0.900.15-0.02-0.07-0.49-0.07-0.13
Balance sheet
Total assets531502545563579548561579
Liabilities756189961088691101
Equity456440455467471461470478
Cash120908286117646278
Long-term debt9.78.98.1109.68.47.25.9
Cash flow
Operating cash flow24-6.0212327-221520
Capital expenditure-7.6-4.7-9.3-15-7.2-12-8.7-7.5
Free cash flow17-11127.820-356.612

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +95.4%, weakest 2022 at −45.1%. 3 of 6 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026−$0.13
30 Jul 2026−$0.07
6 May 2026−$0.49
26 Feb 2026−$0.07
3 Nov 2025−$0.02
4 Aug 2025$0.15
5 May 2025−$0.90
27 Feb 2025$0.32
4 Nov 2024$0.08
5 Aug 2024$0.31
2 May 2024−$0.09
28 Feb 2024−$0.09

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€918m
Market cap in trading currency
$1.01bn
Enterprise value
$745m
P/E
–
P/S
2.69
P/B
2.12
EV/Sales
1.98
EV/EBITDA
–
Earnings yield
–
FCF yield
0.4%

Results (last four quarters)

Revenue
$377m
Gross profit
$291m
EBITDA
−$16.4m
Net income
−$23.0m
Earnings per share
−$0.76
Revenue per share
$12.24
Revenue growth
+23.9%
Earnings growth
–

Profitability

Gross margin
77.1%
Operating margin
-7.4%
Net margin
-6.1%
Return on equity
-4.9%
Return on assets
-4.0%

Balance sheet and cash flow

Cash
$278m
Cash per share
$9.01
Financial debt
$10.1m
Debt/equity %
2
Current ratio
5.28
Book value per share
$15.52
Operating cash flow
$39.7m
Free cash flow
$3.96m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
30.8m
Volume
309,215
Avg. volume 3 months
384,837
Relative volume
0.8

Price and technicals

Price
$32.86
1 day
−1.6%
52-week high
$43.04
52-week low
$18.15
Distance to 52-week high
−23.7%
Distance to 52-week low
+81.0%
Distance to 50-day line
−4.5%
Distance to 200-day line
+17.0%
RSI (14)
45
Volatility 1M
53.4%

Performance

1 week
−2.8%
1 month
−1.0%
3 months
−1.8%
6 months
+63.1%
YTD
−15.5%
1 year
−5.2%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has CSTL performed since 07/2019?

$10,000 grew to $15,355 by 20 Nov 2026, which is +6.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CSTL?

Volatility was 66.1% per year, measured on monthly returns. The largest decline from a peak was −88.0%, with the low in 06/2023.

How does CSTL compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.1% per year at 16.2% volatility, CSTL returned +6.0% at 66.1%. The correlation of monthly returns was 0.23; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.